Data presented at ASCO show Galleri detected more early-stage cancers than all existing UK screening programs combined and sharply increased diagnoses in a US real-world study; researchers stress it does not replace standard screening and survival benefits remain unproven

However, an increase in the detection of stage I/II cancers was observed

GRAIL Reports Full Results From NHS-Galleri Trial Demonstrating Substantial Reduction in Stage IV Cancer Diagnoses at 2026 ASCO Annual Meeting